Cargando…
Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases
Autoimmune disease development depends on multiple factors, including genetic and environmental. Abnormalities such as sialylation levels and/or quality have been recently highlighted. The adjunction of sialic acid at the terminal end of glycoproteins and glycolipids is essential for distinguishing...
Autores principales: | Bordron, Anne, Morel, Marie, Bagacean, Cristina, Dueymes, Maryvonne, Pochard, Pierre, Harduin-Lepers, Anne, Jamin, Christophe, Pers, Jacques-Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036829/ https://www.ncbi.nlm.nih.gov/pubmed/33810246 http://dx.doi.org/10.3390/ijms22073402 |
Ejemplares similares
-
Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
por: Morel, Marie, et al.
Publicado: (2022) -
Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations
por: Iperi, Cristian, et al.
Publicado: (2021) -
A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency
por: Hammadi, Mariam, et al.
Publicado: (2010) -
The vertebrate sialylation machinery: structure-function and molecular evolution of GT-29 sialyltransferases
por: Harduin-Lepers, Anne
Publicado: (2023) -
Hyposialylated α1-acid glycoprotein inhibits phagocytosis of feline neutrophils
por: Rossi, G., et al.
Publicado: (2013)